In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Why Wyeth's Talking Up Vaccines

Executive Summary

Given the near-term generic threats to over a third of its US drug revenues and two late-stage set-backs last year, Wyeth's vaccines business--basically the $3 billion-and-growing pneumococcal vaccine Prevnar--matters more than ever before. So, then, does eliminating an imminent competitive threat from GlaxoSmithKline, and a swift switch to follow-on Prevnar 13 in 2010. Indeed, vaccine chiefs at the other four big players-Sanofi-Aventis, Merck & Co. Inc., GlaxoSmithKline PLC, and Novartis AG-are likely to become more prominent, too. Vaccines may still account for only a small minority of revenues at these Big Pharma, but most saw far healthier growth in their vaccines business in 2007 than in therapeutics. That's why Sanofi, according to recent media reports, is out looking for vaccine acquisitions.
Advertisement

Related Content

VBI Vaccines Acquires Epixis To Expand Immunotherapy Pipeline
Talent Squeeze at FDA: Bad News for Drug Reviews, Good News for Merck?
Getting the Bugs Out of Antibiotic R&D: Commercial Implications of a Higher Regulatory Hurdle
How Wyeth Plans to Make Prevnar a $3 Billion Vaccine
Not-For-Profit Makes Business Sense, Too
Not-For-Profit Makes Business Sense, Too
Novartis Buys into New Pharma World Order
Novartis Buys into New Pharma World Order
How Big Pharma is Tackling the R&D Problem
How Big Pharma is Tackling the R&D Problem

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003027

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel